Limits...
Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.

Zhao S, Wu D, Wu P, Wang Z, Huang J - PLoS ONE (2015)

Bottom Line: Pooled data were weighted using the Mantel-Haenszel Fixed-effect model.High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer.High expression of serous IL-10 leads to an adverse survival in most types of cancer.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education; Provincial Key Laboratory of Molecular Biology in Medical Sciences), Zhejiang University, Hangzhou, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

ABSTRACT

Background: IL-10 is an important immunosuppressive cytokine which is frequently elevated in tumor microenvironment. Some studies have reported that overexpression of serous IL-10 is correlated with worse outcome in patients with malignant tumor. Here, we conducted a meta-analysis to assess the prognostic impact of serous IL-10 expression in cancer patients.

Methods: We searched PubMed and EBSCO for studies in evaluating the association of IL-10 expression-in serum and clinical outcome in cancer patients. Overall survival (OS) was the primary prognostic indicator and disease-free survival (DFS) was the secondary indicator. Extracted data were computed into odds ratios (ORs) and 95% confidence interval (CI) or a P value for survival at 1, 3 and 5 years. Pooled data were weighted using the Mantel-Haenszel Fixed-effect model. All statistical tests were two-sided.

Results: A total of 1788 patients with cancer from 21 published studies were incorporated into this meta-analysis. High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer. Subgroup analysis showed that the correlation between serous IL-10 expression and outcome of patients with solid tumors and hematological malignancies are consistent. The association of IL-10 with worse DFS at 1-year (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.006) and 2-year (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) was also identified.

Conclusions: High expression of serous IL-10 leads to an adverse survival in most types of cancer. IL-10 is a valuable biomarker for prognostic prediction and targeting IL-10 treatment options for both solid tumors and hematological malignancies.

No MeSH data available.


Related in: MedlinePlus

Selection of studies included in the analysis.IL–10 = interleukin–10.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595202&req=5

pone.0139598.g001: Selection of studies included in the analysis.IL–10 = interleukin–10.

Mentions: The search results have been shown in Fig 1. The primary literature research retrieved 5114 records. After screening the title of citations, 3010 records were excluded because of the non-relevance with the theme and duplicated literatures. Next, 2083 citations were excluded after screening abstracts of the records. Then we read carefully the full text of the left citations and at last 21 studies were included.


Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis.

Zhao S, Wu D, Wu P, Wang Z, Huang J - PLoS ONE (2015)

Selection of studies included in the analysis.IL–10 = interleukin–10.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595202&req=5

pone.0139598.g001: Selection of studies included in the analysis.IL–10 = interleukin–10.
Mentions: The search results have been shown in Fig 1. The primary literature research retrieved 5114 records. After screening the title of citations, 3010 records were excluded because of the non-relevance with the theme and duplicated literatures. Next, 2083 citations were excluded after screening abstracts of the records. Then we read carefully the full text of the left citations and at last 21 studies were included.

Bottom Line: Pooled data were weighted using the Mantel-Haenszel Fixed-effect model.High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer.High expression of serous IL-10 leads to an adverse survival in most types of cancer.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute (Key Laboratory of Cancer Prevention & Intervention, National Ministry of Education; Provincial Key Laboratory of Molecular Biology in Medical Sciences), Zhejiang University, Hangzhou, China; Department of Oncology, Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou, China.

ABSTRACT

Background: IL-10 is an important immunosuppressive cytokine which is frequently elevated in tumor microenvironment. Some studies have reported that overexpression of serous IL-10 is correlated with worse outcome in patients with malignant tumor. Here, we conducted a meta-analysis to assess the prognostic impact of serous IL-10 expression in cancer patients.

Methods: We searched PubMed and EBSCO for studies in evaluating the association of IL-10 expression-in serum and clinical outcome in cancer patients. Overall survival (OS) was the primary prognostic indicator and disease-free survival (DFS) was the secondary indicator. Extracted data were computed into odds ratios (ORs) and 95% confidence interval (CI) or a P value for survival at 1, 3 and 5 years. Pooled data were weighted using the Mantel-Haenszel Fixed-effect model. All statistical tests were two-sided.

Results: A total of 1788 patients with cancer from 21 published studies were incorporated into this meta-analysis. High level of serum IL-10 was significantly associated with worse OS at 1-year (OR = 3.70, 95% CI = 2.81 to 4.87, P < 0.00001), 3-year (OR = 3.33, 95% CI = 2.53 to 4.39, P < 0.0001) and 5-year (OR = 2.80, 95% CI = 1.90 to 4.10, P < 0.0001) of cancer. Subgroup analysis showed that the correlation between serous IL-10 expression and outcome of patients with solid tumors and hematological malignancies are consistent. The association of IL-10 with worse DFS at 1-year (OR = 3.34, 95% CI = 1.40 to 7.94, P = 0.006) and 2-year (OR = 3.91, 95% CI = 1.79 to 8.53, P = 0.0006) was also identified.

Conclusions: High expression of serous IL-10 leads to an adverse survival in most types of cancer. IL-10 is a valuable biomarker for prognostic prediction and targeting IL-10 treatment options for both solid tumors and hematological malignancies.

No MeSH data available.


Related in: MedlinePlus